Info
Dr. David Spigel, Sarah Cannon Cancer Center, offers his perspective on the agents he feels most likely to become clinical tools against lung cancer over the next few years.
8 anni fa
#afatinib, #alk, #cancer, #cancergrace, #cannon, #center, #david, #egfr, #grace, #gracecast, #immunotherapy, #inhibitor, #kras, #ldk, #mek, #met, #pd1, #pdl1, #sarah, #spigel
Scopri di più
Cerca
